Literature DB >> 28632411

The Effect of Dexamethasone Intravitreal Implant on Retinal Nerve Fiber Layer in Patients Diagnosed with Branch Retinal Vein Occlusion.

Orhan Ayar1, Atilla Alpay1, Yaran Koban2, Mehmet Orcun Akdemir1, Serpil Yazgan1, Sılay Canturk Ugurbas1, Suat Hayri Ugurbas1.   

Abstract

PURPOSE: To evaluate the effect of a single dose of intravitreal dexamethasone (DEX) implant on retinal nerve fiber layer (RNFL) thickness in patients with branch retinal vein occlusion (BRVO) in a 6-month period.
MATERIALS AND METHODS: This retrospective observational study included the patients with BRVO who received intravitreal DEX implant and whose assessment included the baseline RNFL thickness measurements. The data of 26 eyes of 24 patients were retrospectively analyzed. Spectral domain optic coherence tomography was used to measure peripapillary RNFL thickness in six regional subfields. Intraocular pressure (IOP) values at each visit were recorded. The data of single dose DEX implant during 6 months were assessed.
RESULTS: The mean preoperative and postoperative 6th month nasal RNFL values were 85.4 ± 23.0 μm and 82.1 ± 17.6 μm, respectively, and the difference between the measurements was not statistically significant (p = 0.372). There was a slight decrease in the mean RNFL values postoperatively compared to the baseline values in all quadrants except supero-temporal quadrant; however, none of them reached statistically significant level (p > 0.05). The mean IOP values before and 6 months after implantation were 15.7 ± 2.9 mmHg and 16.5 ± 4.2 mmHg, respectively. The difference between the 6th month IOP values and baseline IOP values was not statistically significant (p = 0.236).
CONCLUSION: Intravitreal DEX implant seems to have no adverse effect on RNFL thickness in BRVO patients in a 6-month period.

Entities:  

Keywords:  Dexamethasone; intravitreal implant; optic coherence tomography; retinal nerve fiber layer; retinal vasculary occlusion

Mesh:

Substances:

Year:  2017        PMID: 28632411     DOI: 10.1080/02713683.2017.1313430

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  4 in total

Review 1.  Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature.

Authors:  Claudio Iovino; Rodolfo Mastropasqua; Marco Lupidi; Daniela Bacherini; Marco Pellegrini; Federico Bernabei; Enrico Borrelli; Riccardo Sacconi; Adriano Carnevali; Rossella D'Aloisio; Alessio Cerquaglia; Lucia Finocchio; Andrea Govetto; Stefano Erba; Giacinto Triolo; Antonio Di Zazzo; Matteo Forlini; Aldo Vagge; Giuseppe Giannaccare
Journal:  Pharmaceutics       Date:  2020-07-26       Impact factor: 6.321

2.  Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries.

Authors:  Sarah Lebrize; Louis Arnould; Abderrahmane Bourredjem; Catharina Busch; Matus Rehak; Pascale Massin; Joao Barbosa-Breda; Marco Lupidi; Cesare Mariotti; Mahmoud Hamza; Alice Grise-Dulac; Pierre-Henry Gabrielle; Stephanie Baillif; Catherine Creuzot-Garcher
Journal:  Ophthalmol Ther       Date:  2022-04-15

3.  The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis.

Authors:  Victor A de Vries; Fabiana L Bassil; Wishal D Ramdas
Journal:  Sci Rep       Date:  2020-08-06       Impact factor: 4.379

4.  Comparison of Anatomical and Functional Outcomes of Intravitreal Dexamethasone Implant between Phakic and Pseudophakic Eyes with Diabetic Macular Edema.

Authors:  Havva Kaldırım; Fatma Savur; Ahmet Kırgız; Kürşat Atalay
Journal:  Korean J Ophthalmol       Date:  2020-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.